Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noac141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Dana Messinger und 37 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Michigan Medical School (UMMS), Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NHGRI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis and limited understanding of the mechanism behind tumor invasion. Previous reports demonstrate upregulation of the protein ID1 with H3K27M and ACVR1 mutations in DMG, but this has not been confirmed in human tumors or therapeutically targeted.
Methods
Whole exome, RNA, and ChIP-sequencing was performed on the ID1 locus in DMG tissue. Scratch-assay migration and transwell invasion assays of cultured cells were performed following shRNA-mediated ID1-knockdown. In vitro and in vivo genetic and pharmacologic [cannabidiol (CBD)] inhibition of ID1 on DMG tumor growth was assessed. Patient-reported CBD dosing information was collected.
Results
Increased ID1 expression in human DMG and in utero electroporation (IUE) murine tumors is associated with H3K27M mutation and brainstem location. ChIP-sequencing indicates ID1 regulatory regions are epigenetically active in human H3K27M-DMG tumors and prenatal pontine cells. Higher ID1-expressing astrocyte-like DMG cells share a transcriptional program with oligo/astrocyte-precursor cells (OAPCs) from the developing human brain and demonstrate upregulation of the migration regulatory protein SPARCL1. Genetic and pharmacologic (CBD) suppression of ID1 decreases tumor cell invasion/migration and tumor growth in H3.3/H3.1K27M PPK-IUE and human DIPGXIIIP* in vivo models of pHGG. The effect of CBD on cell proliferation appears to be non-ID1 mediated. Finally, we collected patient-reported CBD treatment data, finding that a clinical trial to standardize dosing may be beneficial.
Conclusions
H3K27M-mediated re-activation of ID1 in DMG results in a SPARCL1+ migratory transcriptional program that is therapeutically targetable with CBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Michigan Medical School (UMMS), Ann Arbor, Michigan, USA.
- Department of Neurology, University of Michigan Medical School (UMMS), Ann Arbor, Michigan, USA.
- Department of Pathology, University of Michigan Medical School (UMMS), Ann Arbor, Michigan, USA.
- Cancer Research, California Pacific Medical Center Research Institute; San Francisco, California, USA.
- Arthur and Sonia Labatt Brain Tumour Research Centre and Division of Pathology, Hospital for Sick Children, Toronto, Canada.
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Kathleen Dorris, Carl Koschmann
Förderung
- NINDS NIH HHS
- NHGRI NIH HHS
- NCI NIH HHS
- ChadTough Defeat DIPG Foundation
- Joan and David Evans Prosper Road Foundation
- NINDS
- Department of Defense Grant
- University of Michigan Chad Carr Pediatric Brain Tumor Center
Zitieren
APA
Messinger, D., Harris, M. K., Cummings, J. R., Thomas, C., Yang, T., Sweha, S. R., Woo, R., Siddaway, R., Burkert, M., Stallard, S., Qin, T., Mullan, B., Siada, R., Ravindran, R., Niculcea, M., Dowling, A. R., Bradin, J., Ginn, K. F., Gener, M. A. H., …, & Yadav, V. N. (2023). Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac141
Vancouver
Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, et al. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac141
BibTeX
@article{Messinger2023,
author = {Messinger, Dana and Harris, Micah K and Cummings, Jessica R and Thomas, Chase and Yang, Tao and Sweha, Stefan R and Woo, Rinette and Siddaway, Robert and Burkert, Martin and Stallard, Stefanie and Qin, Tingting and Mullan, Brendan and Siada, Ruby and Ravindran, Ramya and Niculcea, Michael and Dowling, Abigail R and Bradin, Joshua and Ginn, Kevin F and Gener, Melissa A H and Dorris, Kathleen and Vitanza, Nicholas A and Schmidt, Susanne V and Spitzer, Jasper and Li, Jiang and Filbin, Mariella G and Cao, Xuhong and Castro, Maria G and Lowenstein, Pedro R and Mody, Rajen and Chinnaiyan, Arul and Desprez, Pierre-Yves and McAllister, Sean and Dun, Matthew D and Hawkins, Cynthia and Waszak, Sebastian M and Venneti, Sriram and Koschmann, Carl and Yadav, Viveka Nand},
title = {Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noac141}
}
EUVIMED